BC Psychosis Program Biobank and Database for Investigating Genetic Polymorphisms of Brain-derived Neurotrophic Factor and Catechol-o-methyl Transferase and Their Associations With Psychosis Disorder
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Psychosis
- Sponsor
- University of British Columbia
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies.
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-o-methyl transferase (COMT) are predictive of psychosis disorder severity, symptomology, and resolution in patients at BCPP. A secondary objective will be to form a biorepository of blood and saliva samples from patients at BCPP so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.
Detailed Description
This is a population-based, genetic-association, candidate polymorphism study. It will involve a prospective and a retrospective component. A blood draw or saliva sample will be performed during the participant's admission to BCPP, which may occur at any point during the participant's length of stay. When a participant has been deemed 'Ready for Discharge' by his/her attending psychiatrist at BCPP, a full phenotype will be obtained via retrospective chart review. Genetic analyses and determination of protein levels will be performed after chart review. Following fulfillment of the primary study objective, the remaining blood and saliva samples will be stored in the biobank over the long-term.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Admission to BCPP.
- •Has provided written informed consent.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies.
Time Frame: One visit during participant's stay at BCPP, an expected average of 6 months
A biobank of stored samples will be used to determine the genetic variability in psychosis disorder.
Secondary Outcomes
- Identification of single-nucleotide polymorphisms (SNPs) in the BDNF and COMT genes(One visit during participant's stay at BCPP, an expected average of 6 months)
- Medical Chart Review(One visit during participant's stay at BCPP, an expected average of 6 months)